Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Lucid Diagnostics Inc. Market Cap
Based on ratings from 0 stock analysts, the Lucid Diagnostics Inc. stock price is expected to increase by 362.96% in 12 months. This is calculated by using the average 12-month stock price forecast for Lucid Diagnostics Inc.. The lowest target is $2.5 and the highest is $7.5. Please note analyst price targets are not guaranteed and could be missed completely.
Lucid Diagnostics Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Lucid Diagnostics Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of LUCD.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Mike Matson Needham | Buy | $2.5 | Reiterates | Aug 13, 2024 |
| Kyle Mikson Canaccord Genuity | Buy | $3 | Maintains | Aug 13, 2024 |
| Edward Woo Ascendiant Capital | Buy | $7.5 | Maintains | Jun 6, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $3 | Reiterates | May 15, 2024 |
| Mike Matson Needham | Buy | $2.5 | Reiterates | May 13, 2024 |
| Mike Matson Needham | Buy | $2.5 | Reiterates | Apr 12, 2024 |
| Mike Matson Needham | Buy | $2.5 | Reiterates | Mar 27, 2024 |
| Ross Osborn Cantor Fitzgerald | Overweight | $3 | Maintains | Mar 27, 2024 |
| Mike Matson Needham | Buy | $2.5 | Maintains | Nov 14, 2023 |
| Ross Osborn Cantor Fitzgerald | Overweight | $4 | Reiterates | Sep 26, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $4 | Reiterates | Aug 22, 2023 |
| Mike Matson Needham | Buy | $2.8 | Reiterates | Aug 16, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $4 | Reiterates | Aug 16, 2023 |
| Mike Matson Needham | Buy | $2.8 | Maintains | May 17, 2023 |
| Charles Duncan Cantor Fitzgerald | Overweight | $4 | Maintains | May 17, 2023 |
| Mike Matson Needham | Buy | $2.6 | Reiterates | Apr 21, 2023 |
| Mike Matson Needham | Buy | $2.6 | Maintains | Mar 14, 2023 |
| Mark Massaro BTIG | Buy | $3.5 | Maintains | Nov 18, 2022 |
| Mike Matson Needham | Buy | $3.1 | Maintains | Nov 15, 2022 |
| Mike Matson Needham | Buy | $4.25 | Maintains | Aug 16, 2022 |
When did it IPO
2021
Staff Count
70
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Lishan Aklog M.D.
Market Cap
$38.5M
In 2023, LUCD generated $2.4M in revenue, which was a increase of 544.03% from the previous year. This can be seen as a signal that LUCD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
